Advancing a novel therapeutic for the prevention of hypoglycemia inType 1 diabetes and establishing proof of concept in Type 2 diabetes

Hypoglycemia or low blood sugar is a phenomenon that results from excess insulin or strenuous exercise in diabetic patients. If untreated, this can quickly lead to dizziness, seizures and even death. In healthy individuals, the body is able to compensate for these fluctuations and restore blood sugars to normal levels by lowering insulin and raising glucagon. In those with diabetes, they are unable to do this and struggle with hypoglycemia.

Inhibiting somatostatin signaling in animal models of diabetes

The prevalence of diabetes is growing rapidly and currently, over 60 million people worldwide use insulin treatment to manage their diabetes. However, insulin treatment can result in hypoglycemia or low blood sugar levels. To date only retroactive treatments are available to treat hypoglycemia, which affects an individual’s quality of life and increases the likelihood of recurring bouts of hypoglycemia as well as development of cardiovascular or renal disease.